Picard to Showcase its Total Artificial Heart at the Annual Meeting of the American Heart Association 2025

Rhea-AI Summary

Picard Medical (NYSE American: PMI) will exhibit at the American Heart Association Annual Meeting on November 7–10, 2025 in New Orleans.

The company will showcase the SynCardia Total Artificial Heart (STAH) at booth #3408, present clinical data, discuss patient eligibility and share real‑world patient experiences. CEO Patrick NJ Schnegelsberg highlighted plans to engage physicians and attendees on the device's latest developments and resources for care teams and patients.

News Market Reaction

+6.18%

20 alerts

+6.18% News Effect

+15.1% Peak in 3 hr 11 min

+$14M Valuation Impact

$239M Market Cap

0.2x Rel. Volume

On the day this news was published, PMI gained 6.18%, reflecting a notable positive market reaction. Argus tracked a peak move of +15.1% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $239M at that time.

Data tracked by StockTitan Argus on the day of publication.

TUCSON, Ariz., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced it will exhibit at the annual meeting of the American Heart Association (AHA) being held November 7^th through 10^th in New Orleans, Louisiana. At the annual meeting of the AHA, Picard will showcase its SynCardia™ Total Artificial Heart (or “STAH”), which is the most widely used and extensively studied artificial heart in the world, at booth #3408.

Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc. commented, “We are excited to attend the annual meeting of the American Heart Association to share the latest developments related to our innovative and life-saving artificial heart, the Syncardia Total Artificial Heart, or STAH. We look forward to having discussions with physicians and attendees at AHA about patient eligibility, the latest clinical data and helpful resources, and sharing insights from patients who have had real-world experiences with the STAH.”

About the American Heart Association (AHA) and its Annual Meeting

#AHA25 brings together the full spectrum of cardiovascular science—from foundational science and translational breakthroughs to clinical trials and real-world application.

Each year, thousands of professionals come together to exchange ideas, build lasting collaborations, and accelerate progress in cardiovascular health on a global scale.

The AHA has grown into the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. A shared focus on cardiovascular health unites its more than 35 million volunteers and supporters as well as its more than 3,300 employees. Learn more here.

The AHA has invested more than $6 billion in research, making it the largest not-for-profit funding source for cardiovascular and cerebrovascular disease research next to the federal government.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This release may contain forward-looking statements within the meaning of federal securities laws. Such statements are based on current expectations and are subject to risks and uncertainties that may cause actual results to differ materially. The Company undertakes no obligation to update or revise any forward-looking statements.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When and where will Picard Medical (PMI) exhibit the SynCardia Total Artificial Heart in 2025?

Picard will exhibit at the AHA Annual Meeting in New Orleans from November 7–10, 2025.

What booth will Picard Medical (PMI) use to showcase the STAH at AHA 2025?

Picard will showcase the SynCardia Total Artificial Heart at booth #3408.

Will Picard Medical (PMI) present clinical data about the SynCardia Total Artificial Heart at AHA 2025?

Yes. Picard plans to discuss the latest clinical data and patient eligibility with physicians and attendees.

What topics will Picard Medical (PMI) cover about the STAH at the AHA meeting?

Picard will cover patient eligibility, recent clinical data, resources for clinicians, and real‑world patient experiences.

How can clinicians learn more or speak with Picard Medical (PMI) about the STAH at AHA 2025?

Clinicians can visit booth #3408 at the AHA meeting to speak with company representatives and review materials.